Key facts
- It has raised $25.0M; the latest was Seed Round ($25.0M) in Feb 2026.
- Notable investors include Transpose Platform Management, Mana Ventures, Builders VC, Primary Venture Partners, Refactor Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for The Biological Computing
- ·The full record, as it builds
Funding rounds
No funding rounds for The Biological Computing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About The Biological Computing
Operator of a biological computing company intended to evolve artificial intelligence by integrating living neurons into modern AI workflows, improving efficiency, scalability and algorithm discovery. The company offers biological adapters and an algorithm discovery platform that uses real neurons to enrich data representations and enhance foundation models, distinguishing itself by bridging biological systems with state-of-the-art AI, enabling customers to achieve measurable benchmark gains, reduce training costs and uncover new architectures beyond transformers.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2022
- Employees
- 22
- Website
- tbc.co/
- Ownership
- Privately Held (backing)
The Biological Computing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in The Biological Computing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on The Biological Computing in its N-PORT filings yet. We sweep new filings monthly.